Pharmaceutical

Servier and Black Diamond sign deal for solid tumours therapy

Servier and Black Diamond Therapeutics have signed a licencing agreement for targeted therapy, BDTX-4933, aimed at addressing solid tumours.

Mar 21, 2025 - 06:00
Servier and Black Diamond sign deal for solid tumours therapy
Servier and Black Diamond Therapeutics have signed a licencing agreement for targeted therapy, BDTX-4933, aimed at addressing solid tumours.
Read the original article

Tags:

Previous Article

Sanofi outlays $1.9bn to purchase Dren Bio’s bispecific antibody

Next Article

International Reference Pricing (IRP) 2024: A year in review

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Delivery tech remains challenging with gene therapies for brain disorders

Delivery tech remains challenging with gene therapies f...

Mar 22, 2024

Diabetes duration has minimal impact on SGLT2 inhibitor efficacy, as per new analysis

Diabetes duration has minimal impact on SGLT2 inhibitor...

Sep 2, 2024

Pfizer launches digital healthcare platform to streamline access

Pfizer launches digital healthcare platform to streamli...

Aug 29, 2024